TWA
BCYC

TCI Wealth Advisors’s Bicycle Therapeutics BCYC Stock Holding History

TCI Wealth Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-73
Closed -$2.16K – 2529
2022
Q4 		$2.16K Buy
+73
New +$1.96K ﹤0.01% 1956

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCI Wealth Advisors's BCYC Position: Q1 2023 in Review

TCI Wealth Advisors sold out of Bicycle Therapeutics (BCYC) in Q1 2023, closing a stake of 73 shares — an estimated $2.16K sold.

TCI Wealth Advisors first reported a position in BCYC in Q4 2022 and held it in 1 quarter. The position peaked at $2.16K in Q4 2022. 89 funds tracked by Wall St. Rank hold BCYC as of Q1 2023.

  • TCI Wealth Advisors reported no remaining Bicycle Therapeutics position as of Q1 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 73 Bicycle Therapeutics shares in Q1 2023, an estimated $2.16K.
  • TCI Wealth Advisors first reported a position in Bicycle Therapeutics in Q4 2022 and held it in 1 quarter.
  • TCI Wealth Advisors's Bicycle Therapeutics position peaked at $2.16K in Q4 2022.
  • 89 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2023.

Based on TCI Wealth Advisors's 13F filing for Q1 2023, filed 3 May 2023.